Disclosed is a pharmaceutical composition comprising i) a dopamine agonist and ii) a L-DOPA derivative in combination in form of a liquid preparation. The pharmaceutical composition comprises a dopamine agonist selected from the group comprising apomorphine, ropinirole, rotigotine, pramipexole, and piribedile and a L-DOPA derivative selected from L-DOPA, selectively and/ or partially deuterated L-DOPA derivatives, as well as physiologically acceptable salts of the aforementioned L-DOPA derivatives. The pharmaceutical composition is provided in a form of a parental application selected from infusions, injections or an application via a gastric tube. The pharmaceutical composition is used for the treatment of Parkinson's disease, of restless leg syndrome, of dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormones, for the treatment of neurological symptoms of chronic manganese intoxication, of amyotrophic lateral scleroses and of multiple system atrophy.La présente invention concerne une composition pharmaceutique comprenant i) un agoniste de la dopamine et ii) un dérivé de L-DOPA associé sous la forme d'une préparation liquide. Ladite composition pharmaceutique est utilisée pour traiter la maladie de Parkinson, le syndrome des jambes sans repos, la dystonie, pour inhiber la sécrétion de prolactine, pour stimuler la libération d'hormones de croissance, pour traiter des symptômes neurologiques de l'intoxication chronique par le manganèse, la sclérose latérale amyotrophique et l'atrophie multisystématisée.
